Similar to the striking clinical and pathological response observed in the reported TN IBC patient treated with systemic neoadjuvant anti-PD-1 therapy [14], we also observed a robust clinical efficacy of neoadjuvant ISV eCPMV immunotherapy leading to tumor reduction in all five treated IMC dogs. The gene discussed is PDCD1; the disease is neoplasm.